中图分类号R979.1；R737.25 文献标志码A 文章编号 1001-0408(2025)13-1683-06

    DOI 10.6039/j.issn.1001-0408.2025.13.22

    Progress in the application of microtubulin inhibitors in prostate cancer

    GUO Nan，DOU Baokai，ZHANG Jing(Dept.of Pharmacy，Provincial Hospital Afiliated to Shandong Firs MedicalUniversity，Jinan ，China)

    ABSTRCTWhenprostatecancer(PCa)progreses tothemetastaticcastration-resistantstage，significantchalengesarisein clinicaltreatment.Microtubulinibitorshavebcomefis-liedugsforthetreamentofmetastaticastratio-resistantPCaduto their uniqe mechanismofaction.Among them，taxanes (.g.docetaxeland cabazitaxel)remainstandardcare with proven survival benefits，whileothermicrotubuleinhbitors(e.g.vincristine，colchicine)showlimitedclinicalutiltyduetotoxicity.Curently，the clinicalappoachprimarilyemploysdocetaxel-basedtripletherapyandcombinedwithimmunecheckpointinhbitorstoimprovethe prognosisofPCapatients，reversetheimmunosuppresive stateof the tumor microenvironment，and enhance therapeutic eicacy. DespitetheremarkableclinicaleffcacyofmicrotubuleinhibitorsinthetreatmentofPCa，theemergenceofdrugresistancehas limitedtheirlong-termaplication.Toaddressthisisue ......